[ONTX] Onconova Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.39 Change: 0.03 (1.27%)
Ext. hours: Change: 0 (0%)

chart ONTX

Refresh chart

Strongest Trends Summary For ONTX

ONTX is in the medium-term down -67% in 3 months and down -87% in 5 months and down -93% in 1 year. In the long-term down -95% in 2 years and up 30069% in 21 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -8.8% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-156.2% ROE-487.72% ROI
Current Ratio3.38 Quick Ratio Long Term Debt/Equity Debt Ratio0.92
Gross Margin Operating Margin-12282.7% Net Profit Margin-12279.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-9.85 M Gross Profit
Net Profit-12.34 M Operating Profit-12.35 M Total Assets36.71 M Total Current Assets36.35 M
Total Current Liabilities10.76 M Total Debt Total Liabilities24.95 M Total Revenue110 K
Technical Data
High 52 week5.78 Low 52 week0.3 Last close0.3 Last change-24.58%
RSI26.62 Average true range0.06 Beta0.13 Volume18.76 K
Simple moving average 20 days-37.42% Simple moving average 50 days-66.09% Simple moving average 200 days-88.69%
Performance Data
Performance Week-16.19% Performance Month-64.92% Performance Quart-86.53% Performance Half-90.77%
Performance Year-92.55% Performance Year-to-date-85.7% Volatility daily10.4% Volatility weekly23.26%
Volatility monthly47.67% Volatility yearly165.14% Relative Volume157.7% Average Volume426.28 K
New High New Low

News

2020-01-03 13:27:41 | Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market

2020-01-02 13:48:43 | Bucks County biopharm firm plans $10M stock sale

2019-12-31 11:30:10 | Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market

2019-12-23 19:33:30 | Onconova Therapeutics, Inc. ONTX Is Burning These Hedge Funds

2019-12-19 13:44:55 | Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market

2019-12-18 09:05:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market

2019-12-18 09:00:10 | Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand

2019-12-17 07:30:10 | Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil

2019-12-10 15:07:58 | Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market

2019-12-09 09:00:10 | Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical T

2019-12-09 08:00:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market

2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

2019-12-06 08:49:10 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 6, 2019: TSLA, ONTX, XHB, BIG, SFIX

2019-12-06 07:30:10 | Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

2019-11-25 09:26:13 | Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering

2019-11-22 14:46:50 | Bucks County biopharm firm enters into licensing deal, embarks on stock sale

2019-11-21 11:23:16 | Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering

2019-11-21 10:16:12 | Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada

2019-11-07 07:30:00 | Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes MDS at the ASH 2019 Annual Meeting & Exposition

2019-10-24 07:30:05 | Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update

2019-09-24 10:15:50 | Bucks County biopharm firm opts for private over public stock sale

2019-09-23 08:52:19 | Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock

2019-09-19 07:39:31 | The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO

2019-09-18 10:05:00 | Onconova Therapeutics Announces Termination of Proposed Public Offering

2019-09-16 07:30:00 | Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

2019-08-16 17:26:25 | Edited Transcript of ONTX earnings conference call or presentation 14-Aug-19 1:00pm GMT

2019-08-14 07:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results

2019-08-12 07:30:00 | Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics

2019-08-07 07:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results

2019-08-06 10:30:02 | Onconova Therapeutics ONTX May Report Negative Earnings: Know the Trend Ahead of Q2 Release

2019-06-10 07:30:00 | Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association

2019-05-28 07:30:00 | Onconova Therapeutics Announces Presentations at Three Upcoming Conferences

2019-05-14 18:23:32 | Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT

2019-05-14 07:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results

2019-05-13 12:52:11 | Newtown biopharm firm could reap $50M from Chinese licensing deal

2019-05-13 07:30:00 | Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China

2019-05-07 07:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results

2019-05-06 07:30:00 | Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes MDS 2019 in Copenhagen, Denmark

2019-04-02 07:30:00 | Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9

2019-03-26 15:59:57 | Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT

2019-03-26 07:30:00 | Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results

2019-03-25 07:30:00 | Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes

2019-03-19 07:30:00 | Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results

2019-03-12 07:30:00 | Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA

2019-02-04 08:00:00 | Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City

2019-01-31 07:30:00 | Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City

2019-01-22 07:30:00 | Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL

2019-01-16 13:08:04 | Bucks County biopharm firm names new CEO

2019-01-15 17:15:00 | Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer

2019-01-02 07:30:00 | Onconova Submits Special Protocol Assessment SPA to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine Vidaza® for First-Line Myelodysplastic Syndromes MDS